Regulation of DNA methylation inheritance in colon cancer
Active Grant Awarded
- Award ID
- R50CA315355
- Recipient
-
Van Andel Research Institute UEI QLRCUJ8JTN53
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $119,105
Award facts
- Assistance listing
- 93.396 Cancer Biology Research
- Completion date 6% complete
- Place of performance
- Wyoming, MI 49503, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded Van Andel Research Institute (doing business as VAI) $119,105 on August 6, 2026, through Grant R50CA315355 under Assistance Listing 93.396, Cancer Biology Research. The award is an R50 research specialist grant that provides career stability for Dr. Rochelle Tiedemann, who will continue leading computational and experimental integration efforts across all aims of the project. That project investigates how ubiquitin signaling regulates DNA methylation inheritance and epigenetic reprogramming in colon cancer, and it is linked to R01CA283463. Dr. Tiedemann's work centers on integrative bioinformatic analysis of DNA methylation, chromatin, and transcriptomic datasets, and on the DNMT1 and UHRF1 mechanisms that underpin the project. The source identifies her as the research specialist for this R50 application. The funding is $119,105 obligated, with ultimate completion on July 31, 2031. Place of performance is Wyoming, Michigan 49503. The source describes no sub-recipients for this award.
Description
- Abstract
- Disruptions in the mechanisms that maintain DNA methylation patterns are a hallmark of cancer and contribute to genome instability and tumor suppressor gene silencing; however, the underlying processes that drive cancer progression and influence response to therapy remain incompletely understood. Since 2015, DR. Rochelle tiedemann, the research specialist for this R50 application, has led the integrative bioinformatics and genomic analysis efforts in the NCI-funded research program of unit director DR. Scott rothbart at the van andel institute. This program investigates how ubiquitin signaling regulates DNA methylation inheritance and epigenetic reprogramming in colon cancer (R01CA283463). DR. Tiedemann's unique expertise at the intersection of molecular biology and computational epigenomics has been central to defining the mechanistic and therapeutic dimensions of DNMT1 and UHRF1 function in epigenetic inheritance. DR. Tiedemann's work has been foundational to discoveries driving DR. Rothbart's research program, demonstrating that DNMT1 methyltransferase activity in cells depends on its ability to read ubiquitin and defining how this interaction shapes genome-wide DNA methylation maintenance. Through the development of experimental models and integrative bioinformatic analysis of DNA methylation, chromatin, and transcriptomic datasets, she revealed that disrupting DNMT1'S ubiquitin reader domain produces global hypomethylation patterns resembling catalytic inactivation, uncovering a novel therapeutic vulnerability. Her analyses further established that UHRF1 ubiquitin ligase activity sustains DNA methylation at low-density cpgs, helping to maintain DNA methylation patterns that are frequently lost in cancer. This R50 research specialist award will provide career stability for DR. Tiedemann to continue leading critical computational and experimental integration efforts across all aims of DR. Rothbart's NCI-funded research program: defining ubiquitin signaling networks that regulate DNA methylation inheritance (aim 1), establishing the oncogenic potential of UHRF1 overexpression in colon cancer (aim 2), and investigating the role of histone ubiquitin-methylation crosstalk in resistance to DNA hypomethylation therapy (aim 3). This work incorporates genetically engineered mouse models to determine how disruption of ubiquitin-dependent DNA methylation maintenance influences tumor initiation, progression, and therapeutic response in physiologically relevant in vivo systems. In addition to leading bioinformatic efforts, DR. Tiedemann will continue to train and mentor junior scientists in data analysis and integrative study design. These studies will reveal fundamental causes and consequences of abnormal DNA methylation signaling in colon cancer and identify new therapeutic strategies to enhance the efficacy of DNA hypomethylation therapy for patients.
Quick answers
Who received award R50CA315355?
R50CA315355 was awarded to Van Andel Research Institute by National Cancer Institute (National Institutes of Health) on August 6, 2026.
How much is award R50CA315355 worth?
$119,105 has been obligated on R50CA315355.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award